Vonorasan fumarate injection2

Phase 2Small molecule

SShandong New Time Pharmaceutical Co., LTD

Vonorasan fumarate injection2 is one of 35 small molecule programs targeting Peptic ulcer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peptic UlcerActive, not recruiting

Peptic UlcerPhase 2

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Peptic Ulcer

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

5 2

Nexium

DDexcel Pharma Technologies Ltd.

Approved

11 3

Bayer Aspirin

Bayer

Approved

1 4

Protonix

WWyeth-Lederle Vaccines

Approved

7 5

Dexilant

Cytotec

Aciphex

1 8

Zantac 150

Rayos

Advil

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Peptic Ulcer

NCT06783257

Clinical

Trials by Indication[1]

Peptic ulcer1 trial

Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding

Not yet recruiting·SShandong New Time Pharmaceutical Co., LTD·Phase 2·NCT06783257·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vonorasan fumarate injection2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vonorasan fumarate injection2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vonorasan fumarate injection2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong New Time Pharmaceutical Co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong New Time Pharmaceutical Co., LTD

Vonorasan fumarate injection2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Peptic ulcer1 trial

References

Drug Info

Quick Facts

Related News